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Introduction {#sec1}
============

*O*-linked β-*N*-acetyl-~D~-glucosamine (*O*-GlcNAc) transferase (OGT) and hydrolase (OGA) control a dynamic, reversible, and tightly regulated post-translational modification termed *O*-GlcNAcylation ([@bib41]). OGT is abundantly expressed in the brain ([@bib30]) and localizes to synaptosomes ([@bib7]). Accordingly, OGT has been linked to regulation of axonal and dendritic morphology ([@bib12]), axonal transport of mitochondria ([@bib32]) and, at the behavioral level, to response and habituation to environmental stimuli ([@bib36]). These findings implicate *O*-GlcNAcylation in various brain functions, including learning and memory.

Intellectual disability (ID) is a disease defined by early-onset impairment of cognitive function and limitation of adaptive behavior ([@bib34]). The most common causes of ID are monogenic mutations in over 650 genes ([@bib20]). Recently, mutations in the N terminus of human *OGT* have been associated with ID, namely, A319T, L254F, R284P, and Δ155-177 ([@bib5], [@bib29], [@bib39]) ([Figure 1](#fig1){ref-type="fig"}A). Two recent studies have reported that while some of these mutations affect OGT activity *in vitro*, *O*-GlcNAc homeostasis appears to be maintained in patient-derived cells by reduced *OGA* expression ([@bib38], [@bib39]). It is as yet unclear how these ID-associated mutations affect OGT structure and function and result in the ID phenotype.Figure 1*In Vitro* Characterization of OGT~L254F~(A) Schematic representation of OGT highlighting the intellectual disability-associated mutations and all the constructs used in this study.(B) Scatterplot showing OGT activity against deglycosylated HEK-293 cell lysate, with the data averaged from six replicates and the error bars showing SD. See also [Figure S1](#mmc1){ref-type="supplementary-material"}B.(C) Superposition of the TPR~WT/L254F~ crystal structures at the site of mutation. The gray and colored cartoons are that of TPR~WT~ (PDB: [1W3B](pdb:1W3B){#intref0080}; [@bib17]) and TPR~L254F~ (PDB: [6EOU](pdb:6EOU){#intref0085}) structures, respectively.(D) Overlay of the chimeric OGT~WT/L254F~ structures. The wild-type structure is colored gray, while the mutant structure is colored to reflect the positional shift of each C~α~ atom between the two structures.(E) Graph showing the positional shift between equivalent C~α~ atoms between chimeric OGT~WT~ (PDB: [4XIF](pdb:4XIF){#intref0090} \[[@bib31]\] and PDB: [1W3B](pdb:1W3B){#intref0095} \[[@bib17]\]) and OGT~L254F~ (PDB: [4XIF](pdb:4XIF){#intref0100} \[[@bib31]\] and PDB: [6EOU](pdb:6EOU){#intref0105}) as a function of residue number.L, L254F; OGT, *O*-GlcNAc transferase; sTPR, simplified TPR; TPR, tetratricopeptide repeat; W, wild-type.

OGT possesses 13.5 tetratricopeptide repeats (TPRs) at the N terminus, which harbor all currently known ID-associated mutations ([@bib24]) ([Figure 1](#fig1){ref-type="fig"}A). TPR-containing proteins are ubiquitous and functionally versatile ([@bib43]). TPRs were first described in protein phosphatase 5 (PP5), where they negatively regulate catalytic activity in a ligand-dependent manner ([@bib8]). In OGT, the TPRs form a 120-Å superhelix, which serves as a potential interaction surface for substrates and binding partners ([@bib17], [@bib43]). Two modes of interaction have been proposed. The central channel generated by the TPR superhelix has been shown to engage some substrates through an asparagine ladder, which interacts with the carbonyl and amide groups of the substrate backbone in a sequence-independent fashion ([@bib22], [@bib33]). In addition, the superhelical grooves on the TPR superhelix may interact with substrates, with different TPRs recruiting distinct target proteins in a sequence-specific fashion, in a manner similar to HSP70/90 organizing protein ([@bib35]). These two models explain how OGT can modify thousands of intracellular proteins on specific sites while also serving as a scaffold in multi-protein complexes. Here, we demonstrate that the L254F mutation in OGT induces folding defects in the TPR superhelix, suggesting that changes in interactions with substrates and/or binding partners may underpin the ID disease phenotype.

Results and Discussion {#sec2}
======================

The ID-associated mutation L254F ([@bib38]) is located on TPR helix 7, distant from the active site ([Figure 1](#fig1){ref-type="fig"}A). *In vitro* OGT activity was tested with a short acceptor peptide derived from the RB2 protein ([@bib31]). In this assay, the L254F mutation had no effect on steady-state kinetics of OGT (peptide *K*~M~ = 0.6 mM, *V*~max~ = 15 nM/s for both enzymes; [Figure S1](#mmc1){ref-type="supplementary-material"}A). Next, we measured OGT activity against de-*O*-GlcNAcylated HEK-293 cell lysate containing a multitude of substrates for OGT, some of which may be recognized by the superhelical grooves found on OGT TPRs. We observed that addition of recombinant OGT~L254F~ was not able to fully restore the amount of *O*-GlcNAc transfer to that of the OGT~WT~-treated control ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B). Thus, in our hands the ID OGT L254F mutation shows effects on *in vitro* activity.

A single TPR motif consists of an anti-parallel pair of α helices, named helix A and B, which are held together by interactions between conserved residues in the 34-amino-acid consensus sequence W~4~-L~7~-G~8~-Y~11~-A~20~-F~24~-A~27~-P~32~ ([@bib17], [@bib21]). The W~4~-L~7~-G~8~-Y~11~ motif on helix A forms a hydrophobic pocket into which the bulky residue of the A~20~-F~24~-A~27~ motif on helix B is lodged. The OGT TPRs possess two additional features: helix A contains a ladder of conserved asparagines (N~6~) on TPRs 2--13.5; helix B contains a series of large aliphatic residues on TPRs 6--13.5 (Ψ~30~; where Ψ represents Leu, Ile, or Val). While the N~6~ ladder is involved in substrate recognition ([@bib17], [@bib22], [@bib33]), the series of large aliphatic residues (Ψ~30~), of which Leu254 is part, interdigitate with aliphatic residues found at the first position within the TPR motifs (X~1~; where X represents Leu, Ala, or Pro). To investigate structural changes attributable to the L254F mutation, we determined the crystal structure of the mutant TPR domain (TPR~L254F~). Recombinant protein was obtained from *Escherichia coli* using the construct boundaries previously employed to crystallize the wild-type OGT TPR domain (TPR~WT~, [Figure 1](#fig1){ref-type="fig"}A) ([@bib17]). Diffraction data were collected to 1.75 Å ([Table 1](#tbl1){ref-type="table"}) and initial refinement starting from the TPR~WT~ structure required substantial rebuilding of the terminal TPRs, an early indication of considerable conformational changes. Indeed, the overall root-mean-square deviation (RMSD) on 343 C~α~ atoms of the refined TPR~L254F~ structure versus that of TPR~WT~ was 1.6 Å.Table 1Scaling and Model-Building Statistics of the TPR~L254F~ Crystal StructureTPR~L254F~**Data Collection**Space group*C*222~1~Cell dimensions α, β, γ (°)44.00, 203.16, 116.87 a, b, c (Å)90.00, 90.00, 90.00Resolution (Å)46.58--1.75 (1.75--1.78)*R*~sym~ or *R*~merge~0.05 (0.57)*I*/σ*I*13.00 (2.00)Completeness (%)99.70 (99.80)Redundancy4.1 (4.1)**Refinement**Resolution (Å)46.58--1.75 (1.75--1.78)No. of reflections54,404 (3,607)*R*~work~/*R*~free~0.19/0.23No. of atoms3,002 Protein2,722 Ligand/ionNA Water280*B* factors Protein38.40 Ligand/ionNA Water42.52RMSDs Bond lengths (Å)0.02 Bond angles (°)2.00[^2]

In wild-type OGT, L~254~ occupies the interface between the helices of TPR7, with its side chain constricted in a pocket formed by the surrounding residues N~223~, L~225~, Y~228~, and R~250~ ([Figure 1](#fig1){ref-type="fig"}C). Mutation of L~254~ to the bulkier Phe appears to be accommodated in this pocket, however, by causing small changes in torsion angles of the residues lining the pocket and by displacing TPR helix 7B away from helix 7A by 1.5 Å ([Figure 1](#fig1){ref-type="fig"}C). We examined the effects of this change in the context of the full-length protein, modeled by merging the TPR~WT/L254F~ structures and an OGT structure containing the catalytic domain (residues 325--1,038; PDB: [4XIF](pdb:4XIF){#intref0010} \[[@bib31]\]) using the overlapping TPRs (residues 325--381) as superposition anchor ([Figures 1](#fig1){ref-type="fig"}A and 1D). This reveals a deviation from the wild-type TPR geometry that is propagated toward the N terminus ([Figures 2](#fig2){ref-type="fig"}D and 2E). Increasing shifts of the TPRs starting from the mutation site lead to a maximum shift of 12 Å for the N-terminal TPR ([Figures 2](#fig2){ref-type="fig"}D and 2E). Thus, the L254F mutation causes a distortion of the TPR helix.Figure 2Characterization of the Effects of the ID-Associated Mutation on OGT TPR Stability and Dynamics(A) Thermal denaturing curve showing fraction of unfolded TPR~WT~ and TPR~L254F~ constructs as a function of temperature. Data averaged from seven replicates were fitted to a Boltzmann sigmoidal curve equation, with error bars representing SD.(B) Superposition of sTPR~WT~ (gray), sTPR~L254F-C1~ (green), and sTPR~L254F-C2~ (purple), with the B-A′-B′ angle and intra-TPR distance demarcated with solid and dashed lines, respectively. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.(C) Graphs of sTPR~WT~ (left) and sTPR~L254F~ (right) conformational populations in the molecular dynamics simulations, with the χ~1~ dihedral angle of residue 254 shown on the x axis, the intra-TPR repeat distance shown on the y axis, and the angle B-A′-B′ shown as a color scale. The B-A′-B′ values observed in the crystal structures are shown as black dots. Histograms attached to the graph show the distribution of χ~1~ dihedral angles. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.sTPR~L254F-C1~ and sTPR~L254F-C1~, sTPR~L254F~ conformations 1 and 2; sTPR, simplified TPR; TPR, tetratricopeptide repeats.

To investigate possible effects of the L254F mutation on stability of the TPRs, we determined the melting temperatures of TPR~WT~ and TPR~L254F~ using differential scanning fluorimetry. A monophasic, sigmoidal melting curve was obtained for TPR~WT~ with an inflection point (*T*~m~) of 58°C ([Figure 2](#fig2){ref-type="fig"}A). The melting curve for TPR~L254F~ was shifted, yielding a *T*~m~ of 55°C, indicative of reduced thermal stability ([Figure 2](#fig2){ref-type="fig"}A). This is in agreement with previous characterization of OGT~L254F~ in patient-derived cells, where the L254F mutation was found to reduce OGT half-life by 2-fold ([@bib38]). Thus it appears that the L254F mutation destabilizes OGT.

To explore the mechanisms underlying the reduction in thermal stability, we performed atomistic molecular dynamics simulations (2 μs) using a fragment of the TPR~WT/L254F~ crystal structures, comprising TPRs 6, 7, and 8 (residues 189--294; hereafter sTPR~WT~ and sTPR~L254F~, respectively; [Figure 1](#fig1){ref-type="fig"}A). In these simulations we monitored the intra-TPR distance between the C~α~ atoms of L~225~ (the first residue of helix 7A) and L~254~ (the last residue of helix 7B), the TPR6-7 B-A′-B′ angle formed between the C~α~ atoms of residues L~220~, L~225~, and L~254~, and the χ~1~ dihedral angle of residue 254 ([Figure 2](#fig2){ref-type="fig"}B). The intra-TPR distance and the angle B-A′-B′ were stable in the sTPR~WT~ simulations ([Figures 2](#fig2){ref-type="fig"}C, [S2](#mmc1){ref-type="supplementary-material"}, and [S3](#mmc1){ref-type="supplementary-material"}), while in the sTPR~L254F~ simulations higher conformational plasticity was observed, showing a partition between two major conformations ([Figures 2](#fig2){ref-type="fig"}B and 2C). In sTPR~L254F~ conformation 1 (sTPR~L254F-C1~), the F~254~ side chain occupies the same position as observed in the TPR~L254F~ crystal structure, while in sTPR~L254F~ conformation 2 (sTPR~L254F-C2~), the F~254~ phenyl moiety interacts with the side chains of N~223~, L~225~, and Y~228~ and the backbone of the F~224~ and R~250~ ([Figure 2](#fig2){ref-type="fig"}B). In sTPR~L254F-C2~ the F~254~ side chain adopts a different conformation, with its aromatic ring positioned parallel to the N~223~ backbone amide in a manner that enables a phenyl-amide interaction. This is accompanied by a 140° ± 17° shift in the F~254~ χ~1~ dihedral angle, which in turn distorts the TPR geometry, increasing the intra-TPR distance by 2.1 ± 0.1 Å and shifting the B-A′-B′ angle by approximately 21° ± 7° ([Figure 2](#fig2){ref-type="fig"}B). Similar to the conformational rearrangement described for the TPR~L254F~ crystal structure, these local changes propagate through subsequent TPR repeats and modify the overall geometry of the protein. Thus, the L254F mutation destabilizes the interface between TPRs 6 and 7.

The data presented here show that the L254F mutation causes a subtle structural distortion at the mutation site that propagates through the TPR superhelix, resulting in a substantial displacement of the N-terminal TPRs and a markedly increased structural plasticity compared with the TPR~WT~. Although *in vitro* assays show global effects on the *O*-GlcNAc proteome, they are modest. However, given that *OGT* is essential for life from stem cells to vertebrates and resides on the X chromosome, it is likely that only relatively subtle mutations are tolerated in males. Moreover, it is possible that the ID-associated mutations result in misrepresentation of a distinct subset of the *O*-GlcNAc proteome in different cell lineages, or under certain stimuli. In light of this, it is interesting to note that all OGT ID mutations reported to date are at some distance from the active site ([Figure 1](#fig1){ref-type="fig"}A). In addition to effects on the *O*-GlcNAc proteome, it is possible that the conformational changes we observe in the TPRs affect the OGT interactome. For example, mSin3A ([@bib42]), TRAK1 ([@bib16]), TET2, and TET3 ([@bib10]) all rely on the six N-terminal TPRs for their recruitment onto OGT, while Atx-10 recruitment on OGT is mediated by TPRs 6--8 ([@bib25]). The work described here forms a platform for the future dissection of these different roles of OGT.

Significance {#sec3}
============

***O*-GlcNAc was discovered more than three decades ago, and more than 1,000 proteins in the human proteome are known to be *O*-GlcNAc modified. However, there is still a substantial gap in our understanding of how *O*-GlcNAcylation regulates protein function and downstream cellular pathways. An inroad into this became possible with the recent discovery that patients with mutations in OGT suffer from ID, the clearest evidence yet linking *O*-GlcNAc to neuronal function, in addition to previous reports implying dysregulation of *O*-GlcNAc in neurodegeneration. Although several OGT mutations linked to ID have recently been reported, it is not understood how these mutations affect OGT at the molecular level. This article is the first to describe the substantial molecular consequences of such a mutation. The L254F mutation resides in the TPR helix, which facilitates OGT substrate recognition. Using X-ray crystallography we have uncovered that this mutation leads to shifts up to 12 Å in the TPR helix, which ties in with the observed reduction in activity. Furthermore, using differential scanning fluorimetry and molecular dynamics simulations we show that the TPR helix is significantly destabilized, leading to defects in substrate recognition. This is a major advance for the *O*-GlcNAc field as it provides a molecular understanding of this mutation and provides a platform for exploring effects on the *O*-GlcNAc proteome.**

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse monoclonal anti *O*-GlcNAc (RL2)Abcamab2739; RRID:[AB_303264](nif-antibody:AB_303264){#interref0010}Rabbit polyclonal anti HSP90Cell SignallingCat\#4874; RRID:[AB_2121214](nif-antibody:AB_2121214){#interref0015}Rabbit polyclonal anti HSP90Enzo Life SciencesADI-SPA-836-D; RRID:[AB_991589](nif-antibody:AB_991589){#interref0020}Rabbit polyclonal anti OGT (H-300)Santa Cruz Biotechnologysc-32921Goat IRDye® 680RD anti-MouseLICORP/N 925-68070; RRID:[AB_621840](nif-antibody:AB_621840){#interref0025}Donkey IRDye® 800CW anti-RabbitLICORP/N 925-32213; RRID:[AB_621848](nif-antibody:AB_621848){#interref0030}Morpheus® HT-96 Crystal ScreenMolecular DimensionsMD1-47**Bacterial and Virus Strains***E*. *coli* BL21-DE3New England BiotechnologiesC25271**Chemicals, Peptides, and Recombinant Proteins**SYPRO® Orange dyeSigmaS5692-50ULGlcNAcstatin-G (OGA inhibitor)GlycoBioChemGBC10002RB2 (residues 410-422)GlycoBioChemN/A*Cp*OGAGlycoBioChemN/AOGT~WT/L254F~This paperN/ATPR~WT/L254F~This paperN/A**Deposited Data**TPR~L254F~ structureThis paperPDB: [6EOU](pdb:6EOU){#intref0015}**Experimental Models: Cell Lines**HEK-293ATCCCRL-1573**Oligonucleotides**Primer TPR: Forward CTGGGATCCGGCCCGATGGAACT\
GGGCTCATCGTGAAATATCAGThis paperN/APrimer TPR: Reverse GATGCGGCCGCTTAGTCTTGCATT\
TCTTTCAGCGTATTACThis paperN/A**Recombinant DNA**pGEX-6P-1 VectorGE Healthcare28954648pHEX-6P-1 VectorThis paperN/A**Software and Algorithms**Graphpad Prism v5.0GraphPad Software<https://www.graphpad.com/>iMosflm([@bib2])<http://www.ccp4.ac.uk/>CCP4([@bib40])<http://www.ccp4.ac.uk/>REFMAC([@bib37]),<http://www.ccp4.ac.uk/>GROMACS([@bib1]).<http://www.gromacs.org/>MDAnalysis([@bib27])<https://www.mdanalysis.org/>MDTraj([@bib26])<http://mdtraj.org/1.9.0/>**Other**Morpheus® HT-96 Crystal ScreenMolecular DimensionsMD1-47

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Daan M. F. van Aalten (<dmfvanaalten@dundee.ac.uk>).

Experimental Model Details {#sec4.3}
--------------------------

### Cell Lines {#sec4.3.1}

Female HEK-293 cells were obtained from ATCC. Due to the use of HEK-293 lysates solely for biochemistry, the cell line was not further authenticated. The cells were tested negative for mycoplasma contamination (October 2017). HEK-293 cells were grown on 15 cm plates in DMEM (Life Technologies) supplemented with 2 mM L-glutamine (Sigma), 100 units/ml Penicillin and 100 μg/ml Streptomycin (Life Technologies), and 10% foetal calf serum (Labtech).

Method Details {#sec4.4}
--------------

### Molecular Cloning {#sec4.4.1}

The full-length codon optimised OGT was obtained from GenScript and subcloned as a *Bam*HI-*Not*I fragment into pHEX-6P-1 (modified version of pGEX-6P-1 which contains a 6His tag instead of GST). The L254F mutation was introduced using a method similar to the QuikChange site-directed mutagenesis kit by Agilent but using KOD polymerase and *Dpn*I from Fermentas. All inserts were confirmed by DNA sequencing. The TPR region of OGT (residues 26-410) was amplified from both the OGT~WT~ and OGT~L254F~ expression constructs. These were cloned into pGEX-6P-1 as *Bam*HI-*Not*I fragments and the inserts were confirmed by DNA sequencing. Forward and reverse primers used were CTGGGATCCGGCCCGATGGAACTGGGCTCATC-GTGAAATATCAG and GATGCGGCCGCTTAGTCTTGCATTTCTTTCAGCGTATTAC, respectively.

### OGT Expression and Purification {#sec4.4.2}

Full length OGT~WT~ and OGT~L254F~ were expressed in *E*. *coli* BL21-DE3 as N-terminal His fusion proteins as described previously ([@bib39]). Briefly, transformed *E*. *coli* cells were grown in autoinduction medium at 37°C with agitation until OD~600~ reached 0.8, at which point the temperature was lowered to 18°C for overnight incubation. Cells were harvested by centrifugation at 4°C (35 min 4,500 × *g*). Resulting cell pellet was resuspended in base buffer (0.1 M Tris-HCl, pH 7.5, 0.15 M NaCl, 0.5 mM TCEP (tris\[2-carboxyethyl\]phosphine) supplemented with 25 mM imidazole 0.1 mg/ml DNase I and protease inhibitor cocktail (1 mM benzamidine, 0.2 mM PMSF, 5 mM leupeptin), and lysed via continuous flow cell disruptor (three passes at 15,000 PSI). Lysate was clarified by centrifugation (30,000 g for 1 h at 4°C) followed by incubation with 1 ml per litre of culture of Ni^2+^-NTA agarose resin (GE Healthcare) for 2 h at 4°C. The resin was thoroughly washed and eluted with base buffer supplemented with 25 mM and 500 mM imidazole respectively. Eluted protein was dialyzed and cleaved from the His-tag overnight at 4°C in buffer A (0.1 M tris-HCl, pH 8.5, 25 mM NaCl) supplemented with PreScission protease (GE Healthcare), then passed through fresh Ni^2+^-NTA agarose resin. Dialyzed protein was loaded onto 5 ml HiTrap Q Sepharose FF anion exchange resin (GE Healthcare) and eluted with a linear gradient up to 60% of buffer B (0.1 M tris-HCl, pH 8.5, 500 mM NaCl). Peak fractions were pooled, concentrated and further purified via size exclusion chromatography using 300-ml prepacked Superdex™ 200 column (GE Healthcare) equilibrated with base buffer. The peak fractions were concentrated to 10 mg/ml, mixed 1:1 with 50% glycerol, snap-frozen and stored at -80°C until use.

### TPR Expression and Purification {#sec4.4.3}

The TPR region of OGT (residues 26-410), either wild type (TPR~WT~) or bearing the L254F mutation (TPR~L254F~), was expressed and purified as N-terminally GST fusion proteins as described previously ([@bib17]). Briefly, *E*. *coli* BL21-DE3 cells were transformed, grown and harvested as described for the full length OGT constructs. Resulting cell pellet was resuspended in base buffer (20 mM Na-HEPES, pH 7.5, 200 mM NaCl, 2 mM DTT supplemented with 0.1 mg/ml DNase I and protease inhibitor cocktail (1 mM benzamidine, 0.2 mM PMSF, 5 mM leupeptin), prior to being lysed and clarified as described above. Clarified lysate was then incubation with 1 ml per litre of culture of Glutathione Sepharose 4B resin (GE Healthcare) for 2 h at 4°C. The resin was thoroughly washed with base and the recombinant proteins were cleaved on-resin by addition of PreScission protease (GE Healthcare) and overnight incubation at 4˚C. Cleaved protein was eluted, concentrated and further purified via size exclusion chromatography using 300-ml prepacked Superdex™ 200 column (GE Healthcare) equilibrated with base buffer. The peak fractions were concentrated to 30 mg/ml, snap-frozen in liquid nitrogen and stored at -80°C until use.

### TPR Crystallisation and Structural Analysis {#sec4.4.4}

Crystallisation of TPR~L254F~ was performed at 22°C using MRC 96-well sitting drop crystallization plates (Molecular Dimensions) by combining 0.2 μl TPR~L254F~ (in 20 mM Na-HEPES-NaOH pH 7.5, 200 mM NaCl and 2 mM DTT) with 0.2 μl of reservoir solution (0.1 M Na-HEPES and 0.1 M MOPS-HCl pH 7,5, 0.04 M diethylene glycol, 0.04 M triethylene glycol, 0.04 M tetraethylene glycol, 0.04 M pentaethylene glycol, 20 % v/v ethylene glycol and 10 % w/v PEG 4000) (Morpheus®, Molecular Dimensions ([@bib13])). Orthorhombic rod and disc shaped crystals appeared within 1-2 days. Prior to diffraction experiments, individual crystals were flash-frozen in liquid nitrogen without prior cryoprotection. Diffraction data were collected at the European Synchrotron Radiation Facility beamline ID30A-1. Data were processed with iMosflm ([@bib2]) and scaled to 1.75 Å using SCALA ([@bib40]). The structure was solved by molecular replacement using the structure for TPR~WT~ (PDB: [1W3B](pdb:1W3B){#intref0060} [@bib17]) as the search model. The resulting model was initially truncated at both N- and C-termini where the fit of the electron density and the model was poor, and manually rebuilt and refined using Coot ([@bib40]) and REFMAC ([@bib37]), respectively. The editing and refinement of the model was iterated until it was in complete agreement with the data. Scaling and model building statistics can be seen in [Table 1](#tbl1){ref-type="table"}.

### Thermal Denaturing Assay {#sec4.4.5}

Thermal denaturation experiments were performed in triplicate, using constructs encompassing the TPR domain (residues 26-410). 50 μl solutions contained 5 μM protein and 1.1x SYPRO® Orange dye (Sigma) in base buffer of 25 mM HEPES-NaOH pH 7.5, 150 mM NaCl and 0.5 mM TCEP. CFX Connect™ Real-Time System (BIO-RAD) was used to measure fluorescence (λ~ex~ = 530 nm, λ~em~ = 560 nm) while temperature was increased from 25 to 95°C at 1 degree per minute increments. The data were transformed, normalised and fitted to a four-parameter Boltzmann sigmoidal curve using GraphPad Prism 5.0.

### Molecular Dynamics Simulations {#sec4.4.6}

Truncated OGT TPR wild type and L254F constructs comprising TPRs 6-8 (sTPR~WT~ and sTPR~L254F~; residues 189-294, [Figure 1](#fig1){ref-type="fig"}A) were used in molecular dynamics simulations, similar to an approach previously used to simulate sections of the alpha-solenoid HEAT repeat protein importin-β ([@bib19]). Appropriate capping groups were added to N- and C-terminal ends of both sTPR~WT~ and sTPR~L254F~ constructs. The major axes of the sTPR constructs were aligned to the z-axis of a triclinic simulation box a triclinic box of 62.5 x 62.5 x 82.5 Å and solvated using explicit water molecules. Na^+^ and Cl^-^ ions were added in order to neutralise the system at the physiological NaCl concentration of 0.15 mM. The amber99SB-ildn force field ([@bib23]) and virtual sites for hydrogen atoms ([@bib11]) were used. The TIP3P water model was used to model the solvent molecules and Joung and Cheatham III parameters ([@bib18]) were used to model the counter ions. Simulations were carried out with the GROMACS molecular dynamics package, version 5.1.5 ([@bib1]). For each system, the geometry was minimized in four cycles that combined 3500 steps of steepest descent algorithm followed by 4500 of conjugate gradient. Thermalisation of the system was performed in 6 steps of 5 ns, where the temperature was gradually increased from 50 K to 298 K, while the protein was restrained with a force constant of 10 kJ mol^-1^ Å^-2^. Production runs consisted of four replicates of 500 ns simulations for each system (accounting for 2 μs of simulation time per system). Making use of virtual sites, the integration time-step was set to 4 fs. Temperature was kept constant by weakly coupling (t = 0.1 ps) protein and water and ions separately to a temperature bath of 298K with the velocity rescale thermostat of Bussi et al. ([@bib6]). The pressure was kept constant at 1 bar using semi-isotropic Berendsen coupling ([@bib3]). Long-range electrostatic interactions were calculated using the smooth particle mesh Ewald method ([@bib9]) beyond a short-range Coulomb cut-off of 10 Å. A 10-Å cut-off was also set for Lennard-Jones interactions. The LINCS algorithm ([@bib15]) was used to restrain the bonds involving hydrogen and the SETTLE algorithm ([@bib28]) was used to constrain bond lengths and angles of water molecules. Periodic boundary conditions were applied.

### In Vitro O-GlcNAcylation Assays {#sec4.4.7}

Michaelis-Menten kinetics of OGT were measured using a fluorimetric assay as described previously ([@bib4]), with the exception of reduced reaction volume of 25 μl and usage of 384-well plate. As acceptor substrate, a 13 amino acid long sequence from retinoblastoma-like protein 2 (RB2; ~410~KENSPAVTPVSTA~422~; GlycoBioChem) was used. Reactions for Michaelis-Menten kinetics contained 0-768 μM acceptor peptide substrate, 200 μM UDP-GlcNAc and 50 nM OGT in 50 mM HEPES-NaOH pH 7.5, 0.1 mg/ml BSA and 10 μM Na~2~S~2~O~4~. Reactions were stopped before 10% of the acceptor substrate was depleted by addition of 50 μl detection reagent (25 mM HEPES-NaOH pH 7.5, 10 mM NaCl, 15 μM xanthene based Zn(II) complex, 75 μM pyrocathecol violet and 50% methanol). The fluorescence was read using excitation and emission wavelengths of 485 nm and 530 nm, respectively. Data were background corrected and plotted using GraphPad Prism.

Additional *O*-GlcNAcylation assays were performed on de-*O*-GlcNAcylated HEK-293 lysate proteins. Cultured HEK-293 cells were washed twice with ice-cold PBS buffer (Life Technologies) prior to lysis. Cells were lysed by addition of lysis buffer (50 mM Tris-HCl, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton-X100, 1 mM Na~3~VO~4~, 50 mM NaF, 5 mM Na~4~P~2~O~7~, 0.27 M sucrose) supplemented with 1 μM ß-mercaptoethanol, 1 mM benzamidine, 0.2 mM PMSF and 5 mM leupeptin. The lysate was transferred into microfuge tubes and clarified by centrifugation at 4°C (17,000 g for 15 min). The lysate was then treated with 120 μg *Cp*OGA per mg of lysate protein and incubated for 90 minutes at 37°C. *Cp*OGA and endogenous HEK-293 OGA were then neutralised by addition of 250 μM GlcNAcstatin-G, an OGA inhibitor. Reactions were then supplemented with OGT~WT~ or OGT~L254F~ (0.2 μM) in presence of 2 mM UDP-GlcNAc and incubated for an additional 2 h at 37°C. Proteins were resolved by SDS-PAGE (3-8% Tris-Acetate gels; Life Technologies), transferred onto nitrocellulose membrane (GE Healthcare), and probed using *O*-GlcNAc-RL2 (1:1,000 dilution; Abcam), HSP90 (1:5,000 dilution; Cell Signalling or Enzo Life Sciences) and OGT-H300 (1:1,000 dilution; Santa Cruz) primary antibodies and corresponding IRDye associated secondary antibodies (1:10,000 dilution; LI-COR). Resulting signal was quantified using a LI-COR Odyssey scanner and associated quantification software. Data were plotted using GraphPad Prism 5.0.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Michaelis-Menten kinetics of the OGT-catalysed reaction against the peptide substrate derived from RB2 was performed as three technical replicates and repeated two times (data presented in [Figure S1](#mmc1){ref-type="supplementary-material"}A). The *O*-GlcNAc activity assay against deglycosylated HEK-293 cell lysate proteins was repeated six times (data presented in [Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}B). The ThermoFluor assay was performed as seven technical replicates, and repeated two times (data presented in [Figure 2](#fig2){ref-type="fig"}A). For all activity and thermal stability assays, GraphPad Prism was used for calculation of statistics. Error bars represent the standard deviation of the mean in all presented data. The trajectories obtained by the molecular dynamics simulations were analysed with the MDAnalysis (RMSD and RMSF) ([@bib14], [@bib27]) and MDtraj (distances and angles) ([@bib26]) packages. The values reported in the results and discussion sections correspond to the mean values ± standard deviation of the mean.

Data and Software Availability {#sec4.6}
------------------------------

The crystallographic structure has been deposited in RCSB Protein Data Bank (<http://www.rcsb.org/pdb>) under ID code [6EOU](pdb:6EOU){#intref0070}.
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[^1]: Lead Contact

[^2]: Related to [Figures 1](#fig1){ref-type="fig"}C and 1D. Values in parentheses represent the highest-resolution shell.
